Abbott India Limited (ABBOTINDIA): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Abbott India Limited, explained in plain English.
- Abbott India Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- ABBOTINDIA closed at ₹25,695.00 on 19 November 2026.
- Over the past year the shares are down 13.0%, trading between ₹24,650.00 and ₹30,655.00.
- Reported fundamentals show return on equity of 39.92%, a net margin of 22.96%, debt to equity of 3.61.
- Our Pulse grade checklist scores it C (64/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 21.55% with a maximum drawdown of -17.13% and a beta of 0.21 against NIFTY 50.
- Recent coverage: Q2 Results Live Updates: LG Electronics, Bharti Airtel, Abbott India, Astral, Bharat Forge, Berger Paints, Emami, Fortis Healthcare Earnings In Focus
Other Pharma & Healthcare companies: Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon
Last traded values from 19 Nov 2026. Market opens at 9:15 IST.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Abbott India Limited (ABBOTINDIA)
₹25,470
▼ 345 (-1.34%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Weak momentum · 0/51M
-2.67%
3M
-4.18%
6M
-8.79%
1Y
-14.14%
Where it sits in its 52-week range
9%Below 52-week high
15.7%
1.8% above the low
Momentum read
Weak
0/5 checks passed
52-wk high
₹30,205
52-wk low
₹25,030
Market cap
₹54,122 Cr
P/E (trailing)
32.7
Dividend yield
—
ROE
39.92%
Profit margin
22.96%
Revenue growth
11%
Price / Book
12.67
Debt / Equity
3.61
EPS (TTM)
777.81
Book value
₹2009.52
Beta
0.21
Pulse grade: C, 56 out of 100
Momentum
F- ✕Trading above 50-day average
- ✕Trading above 200-day average
- ✕RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
C- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
A- ✓Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (13.82%)
Safety
A- ✓Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹1,951 crore · net profit ₹453 crore · margin 23.2%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
ABBOTINDIA headlines
No ABBOTINDIA stories right now.
ABBOTINDIA filings & announcements
ABBOTINDIA, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
21.53%
Sharpe ratio
-0.88
Sortino ratio
-1.31
Max drawdown
-17.13%
Daily VaR (95%)
-1.95%
CAGR (1Y)
-13.8%
Return skew
0.82
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.